<DOC>
	<DOCNO>NCT02841033</DOCNO>
	<brief_summary>Participants AL Amyloidosis receive drug daratumumab IV infusion weekly two month , every 2 week four month , month . Study treatment may continue disease progression , unacceptable toxicity , decision withdraw trial . Disease evaluation perform every three month disease progression .</brief_summary>
	<brief_title>Daratumumab Treatment Patients With AL Amyloidosis</brief_title>
	<detailed_description>This Phase I/II study intend evaluate safety tolerability infusion daratumumab AL amyloidosis , specifically respect infusion reaction . In addition , investigator would like assess organ response respect cardiac biomarkers proteinuria , well hematologic response time next treatment . Participants AL Amyloidosis receive drug daratumumab IV infusion weekly two month , every 2 week four month , month . Study treatment may continue disease progression , unacceptable toxicity , decision withdraw trial . Disease evaluation perform every three month disease progression .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histological diagnosis primary systemic ( AL ) amyloidosis : 1 . At least one tissue demonstrate positive Congo Red stain characteristic apple green birefringence AND 2 . Evidence clonal plasma cell dyscrasia : . Monoclonal protein serum and/or urine immunofixation electrophoresis AND/OR ii . Abnormal serum free light chain assay AND/OR iii . Clonal plasma cell population bone marrow demonstrate immunohistochemistry , flow cytometry situ hybridization AND c. Evidence organ involvement carpal tunnel syndrome . Confirmation tissue diagnosis sit organ dysfunction encourage , require . Must relapse refractory least one prior treatment regimen proven efficacy treatment AL amyloidosis Must &gt; 18 year age . Must performance status 02 Eastern Cooperative Oncology Group ( ECOG ) criterion Must adequate hepatic function evidence serum bilirubin value &lt; 2.0 mg/dL ; alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &lt; 3x upper limit normal ( ULN ) . Must absolute neutrophil count ≥1000/mm3 , hemoglobin ≥7.5 g/dL , platelet count ≥50×109/L • Renal Insufficiency ( CrCL &lt; 20mL/min ) , calculate CockcroftGault Equation Creatinine Clearance = Sex * ( ( 140 Age ) / ( SerumCreat ) ) * ( Weight / 72 ) Equation parameter sex two discrete value may use calculation . The number parenthesis , e.g . ( 1 ) , represent value use . The default unit measure weight kilogram . Please verify correct unit measure select . Mayo clinic cardiac biomarker stage IIIb Evidence significant cardiovascular condition specify : Btype Natriuretic Peptide ; Nterminal pro btype Natriuretic Peptide ( NTProBNP ) &gt; 8500 ng/L ( Mayo Stage IIIb patient exclude ) New York Heart Association ( NYHA ) classification IIIB IV heart failure Unstable Angina , Arrhythmia , prolong correct QT ( QTc ) interval , symptomatic orthostatic hypotension , supine systolic blood pressure &lt; 90 mm Hg . leave ventricular ejection fraction ( LVEF ) &lt; 40 % Overt multiple myeloma ( &gt; 30 % bone marrow plasmacytosis , extensive ( &gt; 2 ) lytic lesion , hypercalcemia ) . Plan autologous stem cell transplant six month prior study drug ( stem cell collection permit first six month study treatment ) Any form secondary familial ( ATTR ) amyloidosis The presence history another malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated Stage I II cancer patient currently complete remission , cancer patient diseasefree 5 year . Known Human Immunodeficiency Virus ( HIV ) positivity . Pregnant nursing woman . Women men reproductive potential may participate unless agree use effective contraceptive method . Known chronic obstructive pulmonary disease ( COPD ) force expiratory volume one second ( FEV1 ) &lt; 50 % predict normal . Note force expiratory volume one second FEV1 testing required patient suspect COPD . Known moderate severe persistent asthma within past 2 year currently uncontrolled asthma classification</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>